Eye

AMSG Unveils Corporate Rebrand to Support Strategic Vision and Growth Aspirations

Retrieved on: 
Thursday, January 12, 2023
Federation, Competence, Element, Core values, Travel, Office of the Secretary of Defense Identification Badge, Compassion, History, Growth, Primary energy, Eye, Resolve, Courage

AMSG began serving the federal government in 2008 with a single $50,000 contract, and two employees.

Key Points: 
  • AMSG began serving the federal government in 2008 with a single $50,000 contract, and two employees.
  • Today AMSG employs over a hundred employees who support dozens of contracts with revenue surpassing $20 million.
  • These videos emphasize our employee opinions on what it’s like to work at AMSG and what makes AMSG different.
  • In the meantime, AMSG continues to focus on our people and use our core values – Competence, Courage, and Compassion – as our North Star to support our people and customers.

Equipment Leasing and Finance Association Announces Top 10 Equipment Acquisition Trends for 2023

Retrieved on: 
Thursday, January 12, 2023
Aircraft, Fed, Congress, Wind, Element, Public health, ELFA, Housing, Organization, Equipment, Risk, Greenhouse, Growth, Automation, Software, Lease, Research, Computer, Acquisition, Eye, Renewable energy

WASHINGTON, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The Equipment Leasing and Finance Association (ELFA), which represents the $1 trillion equipment finance sector, today revealed its Top 10 Equipment Acquisition Trends for 2023 .

Key Points: 
  • WASHINGTON, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The Equipment Leasing and Finance Association (ELFA), which represents the $1 trillion equipment finance sector, today revealed its Top 10 Equipment Acquisition Trends for 2023 .
  • We are pleased to provide the Top 10 Equipment Acquisition Trends to help businesses make their strategic equipment acquisition plans.”
    ELFA distilled recent research and data, including the Equipment Leasing & Finance Foundation’s 2023 Equipment Leasing & Finance U.S. Economic Outlook, industry participants’ expertise and member input from ELFA meetings in compiling the trends.
  • For an infographic highlighting the Top 10 Equipment Acquisition Trends for 2023, please visit ELFA’s Equipment Finance Advantage website for end-users at https://www.equipmentfinanceadvantage.org/toolkit/10trends.cfm .
  • For forecast data regarding equipment investment and capital spending in the United States, see the Equipment Leasing & Finance Foundation’s 2023 Equipment Leasing & Finance U.S. Economic Outlook at www.leasefoundation.org/industry-resources/u-s-economic-outlook/ .

AVANT Outlines Key Growth Strategies for Trusted Advisors in 2023

Retrieved on: 
Wednesday, January 11, 2023
Gen, Process, XDR, Entrepreneurship, Disaster recovery, MDR, Pathfinder Technology Demonstrator, Education, NOT, City centre, Millennials, Pressure, PAM, Culture, Generation Z, SSE, Knowledge, Pathfinder, Thought, CX, Unified communications as a service, Growth, Unified communications, Creativity, Acceleration, Research, Business continuity planning, Lydecker, Identity management, IAM, Sale, Managed security service, Behavior, Acquisition, Investment, AVANT, Eye, Security, Risk management, Asset management, Online shopping, Financial adviser, CCAA

“Businesses that aren’t already migrating to the As-a-Service model are running to catch up and savvy Trusted Advisors know this.

Key Points: 
  • “Businesses that aren’t already migrating to the As-a-Service model are running to catch up and savvy Trusted Advisors know this.
  • “It’s important for Trusted Advisors to remember that security problems do not exist because of threats, the threats exist because of security problems,” said Semmelroth.
  • “This is why Trusted Advisors can add such tremendous value for their customers with the training, education and resources we provide them here at AVANT.”
    For AVANT and its Trusted Advisors, 2023 will be about making the right investments and embracing the “As a Service” model, including omni-channel communications strategies and security offerings, to unlock more revenue and drive business growth.
  • To enable and guide Trusted Advisors on this journey, AVANT offers a number of resources including AVANT Analytics , training and educational events , AVANT Technology Insights , and Pathfinder .

The Labs on 121 Becomes the First Development to Install View Smart Windows in Harlem’s Growing Life Sciences Cluster

Retrieved on: 
Wednesday, January 11, 2023
Wall Street, Eye, Tenant, GLARE, Sleep, Durst Organization, Health, Region, Headache, Partnership, Growth, Intelligence, Research, View, Inc., TIAA, Science, Dust, Labs, Organic, Incidence, Life, Tumbler (glass), Management

NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Nightingale Properties and Real Estate Equities Corporation announced their new 10-story, 160,000-square-foot office development in uptown Manhattan’s Harlem market, will feature Smart Windows from View, Inc. (Nasdaq: VIEW) (“View”), the leader in smart building platforms and smart glass. The Labs on 121, located at 2226 Third Avenue, marks the second partnership between View and Nightingale, following the 111 Wall Street office redevelopment with InterVest Capital Partners (formerly Wafra Capital Partners). It also represents View’s third project in Manhattan’s Third Avenue office corridor, following the recently completed 825 Third Avenue with the Durst Organization, and 730 Third Avenue with TIAA and Nuveen Real Estate, showcasing View’s accelerating growth in New York City.

Key Points: 
  • New York City has stated its commitment to become a market frontrunner for life sciences through capital support and government incentives.
  • The Labs on 121 represents the latest development in Harlem’s life sciences cluster and the first building in the area to install View technology.
  • Smart glass also offers significant health advantages to employees by reducing the incidence of eyestrain and headaches by over 50 percent.
  • In a recent study, employees working next to View Smart Windows improved their sleep by 37 minutes per night and cognitive function by 42 percent.

GOBEL Celebrates 13 Years as Trendsetting Healthcare Philanthropy Powerhouse

Retrieved on: 
Wednesday, January 11, 2023
Hospital, Benchmarking, Philosophy, GSI, Communication, Health, Artificial intelligence, Water, History, Growth, Patient, Research, Medicine, Acquisition, Eye, Food, Management

ST. PETERSBURG, Fla., Jan. 11, 2023 (GLOBE NEWSWIRE) -- At the end of January 2023, GOBEL will host the G23 Healthcare Philanthropy Innovation Summit in Clearwater Beach, FL.

Key Points: 
  • ST. PETERSBURG, Fla., Jan. 11, 2023 (GLOBE NEWSWIRE) -- At the end of January 2023, GOBEL will host the G23 Healthcare Philanthropy Innovation Summit in Clearwater Beach, FL.
  • The summit, an exclusive event for leaders in healthcare philanthropy, will feature some of the brightest minds in healthcare, technology and philanthropy.
  • And to underscore its burgeoning momentum as an industry leader, GOBEL created its own advisory board of senior healthcare leaders from some of the nation's top healthcare organizations.
  • GOBEL is the world's leading consulting and technology firm in healthcare philanthropy.

SOTI Research Finds Retailers Must Master Hybrid Shopping Experiences to Meet Consumer Expectations

Retrieved on: 
Wednesday, January 11, 2023
Ageing, Consumer demand tests (animals), SVP, Carbon, Omnichannel, Software, Research, Product strategy, Eye, Tech, Retail, Online shopping

Consumers are now looking for retailers to accommodate their personalized shopping preferences, both online and in-store.

Key Points: 
  • Consumers are now looking for retailers to accommodate their personalized shopping preferences, both online and in-store.
  • According to SOTI’s new global research report The Tech Effect: Strengthening the Omnichannel to Meet Consumer Demands , retailers that do not leverage technology to enhance online and in-store shopping experiences risk losing consumers to competitors quicker than in previous years.
  • While emphasizing the strength of e-commerce, the research confirms a consistent leaning towards a hybrid shopping model.
  • In this hybrid shopping model, consumers are looking for retailers to offer enhanced and more personalized experiences.

IBN Recaps 2022 Milestones

Retrieved on: 
Wednesday, January 11, 2023
News, Social media, Communication, IR, Upstream, Environment, Champion, History, Growth, Research, PR, IBN, Eye, Circle, Cryptocurrency

NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- -- via InvestorWire -- IBN , a multifaceted financial news and publishing company for private and public entities, today announces a recap of its milestones in 2022.

Key Points: 
  • NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- -- via InvestorWire -- IBN , a multifaceted financial news and publishing company for private and public entities, today announces a recap of its milestones in 2022.
  • Today, IBN boasts a Dynamic Brand Portfolio of 50+ brands with a collective social media audience that includes millions of followers .
  • Throughout 2022, IBN continued expansion of its audiences and syndication network while helping a growing list of client partners navigate lingering market turbulence stemming from the pandemic.
  • Launch of IBN VR – IBN always has an eye toward the next big thing.

RVL Pharmaceuticals plc Announces Preliminary Fourth Quarter Sequential Growth of 21% and Full Year 2022 UPNEEQ® Net Product Sales

Retrieved on: 
Monday, January 9, 2023
Cardiovascular disease, Security (finance), Xanthine oxidase inhibitor, Hypertension, Orthostatic hypotension, Aneurysm, Eye injury, Glycosidic bond, Focal neurologic signs, Headache, Blood pressure, FDA, Risk, Food and Drug Administration, Ptosis, Hypotension, Glaucoma, Telehealth, Orbit, Blepharoplasty, Marketing, Patient, Food, Growth, Annual report, Metabolism, Horner's syndrome, Duane syndrome, Ophthalmoparesis, Stroke, RVL, Beta blocker, Nature, Eye, Myasthenia gravis, Pharmaceutical industry, Phosphorus

BRIDGEWATER, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced preliminary fourth quarter and full year 2022 net product sales of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, the first and only U.S. Food and Drug Administration (“FDA”)-approved ophthalmic solution for blepharoptosis, or droopy eyelids, of approximately $12.1 million and $36.5 million, respectively. The preliminary fourth quarter 2022 net product sales of UPNEEQ represent a sequential increase of 21% from the third quarter 2022. The Company also announced that from February through year-end 2022 it had received orders from approximately 4,300 cumulative unique medical aesthetics practices.

Key Points: 
  • The preliminary fourth quarter 2022 net product sales of UPNEEQ represent a sequential increase of 21% from the third quarter 2022.
  • “We are proud of our progress in the fourth quarter, notably the continued upward trajectory of net product sales for UPNEEQ.
  • On a full-year basis, we expect our UPNEEQ revenues to exceed $36 million, representing nearly 400% growth over 2021.
  • The financial and operating data for the fourth quarter of 2022 and for the full year 2022 is preliminary and may change.

Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities

Retrieved on: 
Monday, January 9, 2023
Disease, FRDA, Genome, Cystic fibrosis transmembrane conductance regulator, Swelling, CGD, Safety data sheet, Respiratory tract, GAA, Tissue, Cystic fibrosis, CD34, CMC, AAV, Heart, Failure rate, CFTR, Mitochondrion, Culture, DNA, LNP, Safety, Mutation, IPSC, Gene editing, Central nervous system, Hepatocyte, Patient, Degenerative disease, CF, Bronchiole, Neuron, PCSK9, Ataxia, Liver, Human, FXN, Inflammation, Chronic granulomatous disease, Eye, Investment, Prime editing, Vaccine, Pharmaceutical industry, Medical device, IND, WD, Frataxin

CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today provided an update on recent advancements of its Prime Editing technology and progress across its initial pipeline of eighteen programs, and outlined its strategic priorities and expected milestones for 2023.

Key Points: 
  • Today, Prime Medicine announced new preclinical data demonstrating that Prime Editing-mediated removal of pathological repeats in vitro results in correction of hypermethylation at the FXN gene, restoring genetic function back to wild-type levels.
  • Off-target Safety Data: Prime Medicine is progressing a comprehensive suite of assays to evaluate the potential off-target activity of its Prime Editors.
  • Prime Medicine is using PCSK9 as a model system for developing its modular LNP delivery platform to the liver.
  • Prime Medicine expects the following activities and next steps to drive the Prime Editing platform forward:
    Nominate first development candidate for CGD in 1Q 2023.

Biologicals Industry Leader Richard Jones Joins DunhamTrimmer Bio Intelligence as Vice President of Content and Client Engagement

Retrieved on: 
Monday, January 9, 2023
Consulting, Technology, Manufacturing, Professional Services, Marketing, Communications, Agriculture, Natural Resources, Agritech, Environment, Chemicals, Plastics, Partner (business rank), Content, Corporation, Entrepreneurship, Environment and Communications Committee (Iceland), Fruit, Conference, Marketing, Intelligence, Eye, Multimedia

DunhamTrimmer, the global leader in business intelligence for the biocontrol, biostimulant, biofertilizer, and specialty nutrition industries, announced today it has named Richard Jones the company’s new Vice President of Content and Client Engagement.

Key Points: 
  • DunhamTrimmer, the global leader in business intelligence for the biocontrol, biostimulant, biofertilizer, and specialty nutrition industries, announced today it has named Richard Jones the company’s new Vice President of Content and Client Engagement.
  • For more than ten years, Jones led the company’s biologicals content strategy, focusing on developments in biopesticides, macroorganisms, and biostimulants.
  • “I have known and engaged with DunhamTrimmer, and have benefitted from its unparalleled market intelligence for years,” Jones said.
  • I am excited to help build on that foundation as we work together toward an exciting future for the biologicals industry.”